Diabetic kidney disease: Challenges, progress, and possibilities

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 12, 2017, Pages 2032-2045

  Alicic, Radica Z ^a,b   Rooney, Michele T ^a   Tuttle, Katherine R ^a,b,c,d  

^a Providence Medical Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Institute of Translational Health Sciences   (United States)

^d Kidney Research Institute   (United States)

Author keywords

Altered renal hemodynamics; Diabetic nephropathy; Diagnosis; Natural history; Novel therapies; Pathogenesis; Structural changes

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRASENTAN; BARICITINIB; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DULAGLUTIDE; FINERENONE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; MINERALOCORTICOID ANTAGONIST; PARATHYROID HORMONE; PENTOXIFYLLINE; PROTEIN KINASE C; PYR 311; RUBOXISTAURIN; SAXAGLIPTIN; SEMAGLUTIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; ESTIMATED GLOMERULAR FILTRATION RATE; FEEDBACK SYSTEM; FIBROSIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLYCEMIC CONTROL; HEALTH CARE PLANNING; HISTOLOGY; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; INFLAMMATION; KIDNEY FUNCTION; MICROSCOPY; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SYSTOLIC BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMPLICATION; DISEASE EXACERBATION; GLOMERULUS FILTRATION RATE; HYPERTENSION; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 85020046943     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.11491116     Document Type: Article

References (87)

1. Cameron JS: The discovery of diabetic nephropathy: From small print to centre stage. J Nephrol 19[Suppl 10]: S75–S87, 2006
2. USRDS: United States Renal Data System Annual Data Report: Epidemiology of Kidney Disease in the United States, Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases, 2015
3. Reutens AT: Epidemiology of diabetic kidney disease. Med Clin North Am 97: 1–18, 2013
4. World Health Organization: Global Status Report on Non-communicable Diseases, Geneva, Switzerland, World Health Organization, 2014
5. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J: Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305: 2532–2539, 2011
6. Menke A, Casagrande S, Geiss L, Cowie CC: Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 314: 1021–1029, 2015
7. International Diabetes Federation: Diabetes Atlas, 7th Ed., Brussels, Belgium, IDF Executive Office, 2015
8. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL: Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 22: 39–47, 1998
9. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL: Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315: 2284–2291, 2016
10. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, deVaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O’Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope CA 3rd, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2095–2128, 2012
11. Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, Saran R, Wang AY-M, Yang C-W: Chronic kidney disease: Global dimension and perspectives. Lancet 382: 260–272, 2013
12. Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH: Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24: 302–308, 2013
13. Taal MW: Risk factors and chronic kidney disease. In: Brenner and Rector’s The Kidney, 10th Ed., edited by Skorecki K, Amsterdam, Elsevier, 2015, pp 669–692.e7
14. Caramori ML, Parks A, Mauer M: Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 24: 1175–1181, 2013
15. The Diabetes Control and Complications (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 47: 1703–1720, 1995
16. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853, 1998
17. Tonna S, El-Osta A, Cooper ME, Tikellis C: Metabolic memory and diabetic nephropathy: Potential role for epigenetic mechanisms. Nat Rev Nephrol 6: 332–341, 2010
18. Nathan DM; DCCT/EDIC Research Group: The diabetes control and complications trial/epidemiology of diabetes interventions and complications studyat 30 years: Overview. Diabetes Care 37: 9–16, 2014
19. DCCT/EDIC Research Group; de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. NEngl J Med 365: 2366–2376, 2011
20. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577–1589, 2008
21. Bilous R: Microvascular disease: What does the UKPDS tell usabout diabetic nephropathy? Diabet Med 25[Suppl 2]: 25–29, 2008
22. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group: Risk factors for renal dysfunction in type 2 diabetes: U. K. Prospective Diabetes Study 74. Diabetes 55: 1832–1839, 2006
23. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group: Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study. Arch Intern Med 163: 1555–1565, 2003
24. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr., Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J AmSoc Nephrol 16: 3027–3037, 2005
25. Fioretto P, Mauer M: Histopathology of diabetic nephropathy. Semin Nephrol 27: 195–207, 2007
26. Tyagi I, Agrawal U, Amitabh V, Jain AK, Saxena S: Thickness of glomerular and tubular basement membranes in preclinical and clinical stages of diabetic nephropathy. Indian J Nephrol 18: 64– 69, 2008
27. Drummond K, Mauer M; International Diabetic Nephropathy Study Group: The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes 51: 1580–1587, 2002
28. Osterby R, Tapia J, Nyberg G, Tencer J, Willner J, Rippe B, Torffvit O: Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS 109: 751–761, 2001
29. Saito Y, Kida H, Takeda S, Yoshimura M, Yokoyama H, Koshino Y, Hattori N: Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions. Kidney Int 34: 389–396, 1988
30. Stout LC, Kumar S, Whorton EB: Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule. Hum Pathol 24: 77–89, 1993
31. Rossing PFP, Feldt-Rasmussen B, Parving HH: Diabetic nephropathy. In: Brenner and Rector’s The Kidney, 10th Ed., edited by Skorecki K, Chertow GM, Marsden PA, Yu ASL, Taal MW, Philadelphia, Elsevier, pp 1283–1381
32. Fioretto P, Caramori ML, Mauer M: The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 51: 1347–1355, 2008
33. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA; Renal Pathology Society: Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21: 556–563, 2010
34. Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32[Suppl 2]: 64–78, 1983
35. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS GROUP: Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225–232, 2003
36. Gaede P, Tarnow L, Vedel P, Parving H-H, Pedersen O: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and micro-albuminuria. Nephrol Dial Transplant 19: 2784–2788, 2004
37. Pacilli A, Viazzi F, Fioretto P, Giorda C, Ceriello A, Genovese S, Russo G, Guida P, Pontremoli R, De Cosmo S; AMD-Annals Study Group: Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative [pub-lished online ahead of print December 9, 2016]. Diabetes Metab Res Rev doi:10.1002/dmrr.2873
38. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH: Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA 316: 602–610, 2016
39. Klessens CQF, Woutman TD, Veraar KAM, Zandbergen M, Valk EJJ, Rotmans JI, Wolterbeek R, Bruijn JA, Bajema IM: An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int 90: 149–156, 2016
40. Thomas MC, Cooper ME, Rossing K, Parving H-H: Anaemia in diabetes: Is there a rationale to TREAT? Diabetologia 49: 1151– 1157, 2006
41. Moseley KF: Type 2 diabetes and bone fractures. Curr Opin En-docrinol Diabetes Obes 19: 128–135, 2012
42. Foley RN, Hakim RM: Why is the mortality of dialysis patients in the United States much higher than the rest of the world? J AmSoc Nephrol 20: 1432–1435, 2009
43. USRDS: United States Renal Data System Annual Data Report: Mortality, Ann Arbor, MI, USRDS, 2015
44. Tuttle KR, Bruton JL: Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney Int 42: 167–173, 1992
45. Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA: Effect of strict glycemiccontrol onrenal hemodynamicresponse toaminoacids andrenal enlargement ininsulin-dependent diabetes mellitus. N Engl J Med 324: 1626–1632, 1991
46. Tuttle KR, Puhlman ME, Cooney SK, Short RA: Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. Am J Physiol Renal Physiol 282: F103–F112, 2002
47. Grabias BM, Konstantopoulos K: The physical basis of renal fibrosis: Effects of altered hydrodynamic forces on kidney ho-meostasis. Am J Physiol Renal Physiol 306: F473–F485, 2014
48. Premaratne E, Verma S, Ekinci EI, Theverkalam G, Jerums G, MacIsaac RJ: The impact of hyperfiltration on the diabetic kidney. Diabetes Metab 41: 5–17, 2015
49. Tuttle KR: Back to the future: Glomerular hyperfiltration and the diabetic kidney. Diabetes 66: 14–16, 2017
50. Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134: 752– 772, 2016
51. Anonymous: Standards of medical care in diabetes-2016: Summary of revisions. Diabetes Care 39[Suppl 1]: S4–S5, 2016
52. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME: Diabetic kidney disease: A report from an ADA consensus conference. Diabetes Care 37: 2864–2883, 2014
53. National Kidney Foundation: KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60: 850–886, 2012
54. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F; ADVANCE Collaborative Group: Intensive blood glucose control andvascular outcomes in patientswith type 2 diabetes. N Engl J Med 358: 2560–2572, 2008
55. Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr., Probstfield JL, Simons-Morton DG, Friedewald WT; Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559, 2008
56. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, HaywardR, WarrenSR, GoldmanS, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129–139, 2009
57. Papademetriou V, Lovato L, Doumas M, Nylen E, Mottl A, Cohen RM, Applegate WB, Puntakee Z, Yale JF, Cushman WC; ACCORD Study Group: Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney Int 87: 649–659, 2015
58. Wong MG, Perkovic V, Chalmers J, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, Heller S, MacMahon S, Mancia G, Marre M, Matthews D, Neal B, Poulter N, Rodgers A, Williams B, Zoungas S; ADVANCE-ON Collaborative Group: Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON. Diabetes Care 39: 694–700, 2016
59. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr., Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O’Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A, Weiss D, Hramiak I; ACCORD Trial Group: Effect of intensive treatment of hyperglycaemia on microvascular outcomes intype2diabetes: Ananalysis of the ACCOR Drandomisedtrial. Lancet 376: 419–430, 2010
60. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr., Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr., Narva AS, Ortiz E: 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507–520, 2014
61. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869, 2001
62. Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET Investigators: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multi-centre, randomised, double-blind, controlled trial. Lancet 372: 547–553, 2008
63. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P; VA NEPHRON-D Investigators: Combined angiotensin inhibition for the treatment of diabetic nephropathy. NEngl J Med 369: 1892–1903, 2013
64. SPRINT Research Group, Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT: A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373: 2103–2116, 2015
65. Perkovic V, Rodgers A: Redefining blood-pressure targets–SPRINT starts the marathon. N Engl J Med 373: 2175–2178, 2015
66. Cushman WC, Evans GW, Byington RP, Goff DC Jr., Grimm RH Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F; ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585, 2010
67. Rocco MV, Cheung AK: A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists. Kidney Int 89: 261–263, 2016
68. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW: The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28: 2686–2690, 2005
69. Brosius FC, Tuttle KR, Kretzler M: JAK inhibition in the treatment of diabetic kidney disease. Diabetologia 59: 1624–1627, 2016
70. Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Chahin J, Méndez ML, Gallego E, Macía M, del Castillo N, Rivero A, Getino MA, García P, Jarque A, García J: Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial. J Am Soc Nephrol 26: 220–229, 2015
71. de Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, Correa-Rotter R, Kohan D, Lambers Heerspink HJ, Makino H, Perkovic V, Pritchett Y, Remuzzi G, Tobe SW, Toto R, Viberti G, Parving HH: The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 25: 1083–1093, 2014
72. Danielle P: A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Al-trasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy with Atrasentan NCTO1858532. Available at: ClinicalTrials.gov. Accessed April 28, 2017
73. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group: Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 314: 884–894, 2015
74. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators: Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373: 2247–2257, 2015
75. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee, LEADER Trial Investigators: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375: 311–322, 2016
76. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators: Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375: 1834–1844, 2016
77. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117–2128, 2015
78. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators: Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375: 323–334, 2016
79. Bullock A, Burrows NR, Narva AS, Sheff K, Hora L, Lekiachvili A, Cain H, Espey D: Vital signs: Decrease in incidence of diabetes-related end-stage renal disease among American Indians/Alaska natives — United States, 1996–2013. MMWR Morb Mortal Wkly Rep 66: 26–32, 2017
80. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L: Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med 370: 1514–1523, 2014
81. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects with Nephropathy Due to Type 2 Diabetes (PIONEER) NCTO2156843. Available at: ClinicalTrials.gov. Accessed April 27, 2017
82. Maahs DM, Caramori L, Cherney DZI, Galecki AT, Gao C, Jalal D, Perkins BA, Pop-Busui R, Rossing P, Mauer M, Doria A; PERL Consortium: Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allo-purinol study. Curr Diab Rep 13: 550–559, 2013
83. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM: Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA 314: 884–894, 2015
84. Mosenzon O, Leibowitz G, Bhatt DL, Cahn A, Hirshberg B, Wei C, Im K, Rozenberg A, Yanuv I, Stahre C, Ray KK, Iqbal N, Braunwald E, Scirica BM, Raz I: Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 40: 69–76, 2017
85. Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA) NCT01897532, 2016. Available at: ClinicalTrials.gov. Accessed April 27, 2017
86. A Study Comparing Dulaglutide with Insulin Glargine on Glycemic Control in Participants with Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) (AWARD-7) NCT01621178, 2017. Available at: ClinicalTrials.gov, 2017. Accessed April 27, 2017
87. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants with Diabetic Nephropathy (CREDENCE) NCT02065791, 2017. Available at: ClinicalTrials. gov. Accessed April 27, 2017